ISO 10993-1:2025 Revision · Edition 6
Update Your ISO 10993-1 Biological Evaluation to the 2025 Revision (Edition 6)
Align your biological evaluation plan and report with the new ISO 10993-1:2025 revision (Edition 6). We help you translate the updated, risk-based structure — effects instead of endpoints, tighter ISO 14971 integration, explicit risk estimation (severity, probability, uncertainty) and foreseeable misuse — into clear, reviewer-ready documentation across your device portfolio.
Consulting & documentation only
Fast turnaround
Global coverage
When These Situations Happen, It’s Time to Move to ISO 10993-1:2025
Typical situations where a structured transition to the 2025 Edition (Edition 6) becomes critical:
- You need to update existing BEPs/BERs so they reflect the new structure around biological effects instead of the older endpoint lists.
- Your notified body or FDA reviewer is asking how your biological evaluation links to ISO 14971 and explicit risk estimation.
- You manage a portfolio of devices and need consistent, transparent risk estimation scales (severity, probability, uncertainty) across all products.
- You want to document foreseeable misuse and exposure duration in a way that clearly speaks the new ISO 10993-1:2025 language.
- You must demonstrate that your documentation reflects state of the art in the EU while staying aligned with FDA biocompatibility expectations in the US.
Why This Revision Matters Now
The 2025 revision of ISO 10993-1 (Edition 6) does more than reorganize the text. It changes how biological safety reasoning should be presented:
- From endpoints to effects: The focus shifts to biological effects, so your evaluation must clearly trace from device characteristics to potential biological effects and related evidence.
- Tighter ISO 14971 integration: Biological safety is now more explicitly embedded in the overall risk management process — documentation must show this linkage, not just list tests.
- Explicit risk estimation: Regulators expect transparent scales for severity, probability, and uncertainty, including how conservative assumptions are applied.
- Foreseeable misuse and exposure: The revision emphasises realistic but conservative exposure scenarios, including foreseeable misuse and clearly documented exposure durations.
In the EU, the latest edition of ISO 10993-1 is generally treated as state of the art, so your files should reflect the 2025 structure. In the US, you still need to align with FDA’s biocompatibility guidance and recognition status — while showing that your biological evaluation reasoning is consistent with the updated risk-based approach.
How We Turn Your Existing Files Into a 2025-Ready Biological Evaluation
We start from what you already have — your devices, your current BEPs/BERs, chemistry and biological data — and turn it into a clear, Edition 6–aligned package.
Discovery & scoping
Portfolio scan & gap log
BEP/BER update & risk estimation
Transition checklist & reviewer-style QA
What You Receive From the ISO 10993-1:2025 Transition Package
The goal is not generic training, but concrete, reviewer-ready documentation that you can immediately plug into dossiers and technical files.
Who This Service Is For
- Regulatory affairs and quality teams responsible for biological safety documentation.
- Manufacturers with multiple devices that must show consistent application of ISO 10993-1 across the portfolio.
- Materials, toxicology, and clinical partners supporting BEP/BER updates.
- Project leads preparing EU MDR submissions while maintaining alignment with FDA expectations.
- Any internal risk management scales or SOPs we should align with.
What We Need From You
- A list of devices in scope, including intended purpose, clinical context, and patient-contact duration.
- Existing BEPs/BERs, chemical characterization results (where relevant), biological test reports, and prior reviewer feedback.
- Target markets and timelines (EU, US, other regions).
- Any internal risk management scales, templates, or SOPs we should align with.
Why Teams Trust Sobel With ISO 10993-1 Transitions
Sobel is an international regulatory consultancy supporting manufacturers with evidence-based, reviewer-ready submissions for medical devices, IVDs, and cosmetics across the U.S., EU, Brazil, and other key markets. Our work is built to match how reviewers actually read your files.
- Consistent biological evaluation logic across your entire device portfolio.
- Clear linkage between ISO 10993-1, ISO 14971, and overall clinical and risk strategy.
- Documentation that reflects the 2025 revision structure without forcing unnecessary new testing.
- Reviewer-oriented writing that reduces back-and-forth and clarifies acceptance logic.
- Experience bridging EU state-of-the-art expectations with FDA guidance and recognition patterns.
FREQUENTLY ASKED QUESTIONS
Not automatically. The 2025 revision focuses on how you structure and justify your biological evaluation. New tests are only recommended where the updated risk-based analysis and evidence show that risk is not sufficiently controlled or documented.
For a focused set of devices, transitions often take 2–6 weeks from discovery to updated BEP/BER delivery, depending on the size of your portfolio and the completeness of existing data.
In the EU, authorities expect documentation to reflect the latest edition as state of the art, so aligning with the 2025 revision is important. In the US, you should continue to follow FDA biocompatibility guidance while demonstrating that your biological evaluation follows a transparent, risk-based approach consistent with the new standard.
Yes. Many teams start with a limited set of key devices to establish the revised structure and risk estimation scales. Once that pattern is validated, we apply it efficiently across the rest of the portfolio.
Get a Clear, Reviewer-Ready ISO 10993-1:2025 Transition Plan
If ISO 10993-1:2025 (Edition 6) is now the reference point for your biological evaluation, your documentation must show it. We help you move from legacy BEPs/BERs to a transparent, risk-based structure built for current reviewer expectations — without unnecessary testing or confusion.
Contact Us
We would love to speak with you.
Feel free to reach out using the below details.
